Alterations in the composition and metabolic activity of the gut microbiota appear to contribute to the development of obesity and associated metabolic diseases. However, the extent of this relationship remains unknown. Modulating the gut microbiota with non-digestible carbohydrates (NDC) may exert anti-obesogenic effects through various metabolic pathways including changes to appetite regulation, glucose and lipid metabolism and inflammation. The NDC vary in physicochemical structure and this may govern their physical properties and fermentation by specific gut bacterial populations. Much research in this area has focused on established prebiotics, especially fructans (i.e. inulin and fructo-oligosaccharides); however, there is increasing interest in the metabolic effects of other NDC, such as resistant dextrin. Data presented in this review provide evidence from mechanistic and intervention studies that certain fermentable NDC, including resistant dextrin, are able to modulate the gut microbiota and may alter metabolic process associated with obesity, including appetite regulation, energy and lipid metabolism and inflammation. To confirm these effects and elucidate the responsible mechanisms, further well-controlled human intervention studies are required to investigate the impact of NDC on the composition and function of the gut microbiota and at the same time determine concomitant effects on host metabolism and physiology. (1) . In the UK population, it is estimated that 26 % of boys, 25 % of girls, 67 % of men and 57 % of women are currently overweight or obese (1) . Characterised by the accumulation of excess body fat, overweight and obesity are associated with a chronic low-grade systemic inflammation and other adverse metabolic effects. Consequently, the risk of pathologies including CVD, type 2 diabetes mellitus, chronic obstructive pulmonary disease, colon cancer, breast cancer, osteoarthritis, liver and gall bladder disease and reproductive dysfunction, are increased (2) . Overweight and obesity are also thought to increase the risk of common cognitive issues, such as anxiety and depression (3) . Population-based interventions to reduce the prevalence of overweight and obesity are now implemented as part of wider public health strategies in the majority of developed countries worldwide. In the UK, the Department of Health aims to achieve, by 2020, a sustained downward trend in the level of excess weight in children and a downward trend in the level of excess weight averaged across all adults (4) . Such interventions focus primarily on encouraging healthier food choices and increasing physical activity; however, they must compete with the *Corresponding author: M. R. Hobden, email M.R.Hobden@reading.ac.uk Abbreviations: AXOS, arabinoxylan-oligosaccharides; FFAR, free-fatty acid receptor; GLP-1, glucagon-like peptide-1; FOS, fructooligosaccharides; NDC, non-digestible carbohydrate; PYY, peptide YY.